April 23, 2012

Genovis to publish Q1 2012 report ahead of schedule

Regulatory
Genovis has decided to publish the report for Q1 2012 on Wednesday, April 25.

The subscription period for Genovis’ rights issue is April 25 – May 10. Consequently, the Board of Directors for Genovis considers it to be important that shareholders receive the most current information possible about the Company’s earnings and financial position.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 4646 -101235 sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis develops and sells innovative technologies from two unique product portfolios. The first includes enzymes that facilitate development and quality control for applications such as antibody-based drugs. The products launched to date are aimed at customers who work with development of drugs, new diagnostic methods and basic research.

The second consists of nanotechnology in new contrast agents and focuses on design, production and characterization of nanostructures as contrast agents in medical imaging. The nanostructures and methods that Genovis focuses on can also be used as carriers of various substances in the development of new drug delivery methods. The projects are mainly in-house, but also include collaborations with research groups, including at Lund University.

Genovis shares are listed on the First North OMX Nordic Exchange and Thenberg Fondkommission is our certified advisor.

Release
  • Svenska